Acrivon Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ACRV Nasdaq 2830 acrivon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acrivon Therapeutics, Inc.

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities - Apr 17th, 2026 2:00 pm
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 15th, 2026 2:05 pm
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Mar 19th, 2026 5:21 am
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors - Mar 17th, 2026 3:54 pm
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - Mar 3rd, 2026 10:00 am
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Feb 27th, 2026 9:47 am
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Feb 24th, 2026 6:00 am
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - Feb 23rd, 2026 6:00 am
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory - Feb 18th, 2026 6:00 am
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - Jan 23rd, 2026 6:11 am
Penny Stocks To Watch In January 2026 - Jan 19th, 2026 5:05 am
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Jan 18th, 2026 6:18 am
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Jan 8th, 2026 5:30 am
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Jan 7th, 2026 7:40 am
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - Jan 6th, 2026 5:30 am
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - Dec 17th, 2025 7:34 am
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates - Dec 17th, 2025 5:30 am
3 Promising Penny Stocks With Market Caps Over $70M - Dec 11th, 2025 5:05 am
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Nov 28th, 2025 11:26 pm
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 13th, 2025 2:10 pm